Osteoporosis Market and Forecast Analysis Report 2018: Prolia will drive growth of the US market, while Forteo losses will halt growth in Japan and the EU - ResearchAndMarkets.com

DUBLIN--()--The "Osteoporosis Market and Forecast Analysis" report has been added to ResearchAndMarkets.com's offering.

Osteoporosis is the most common metabolic bone disorder, and is characterized by low bone mass accompanied by microarchitectural deterioration of bone tissue. The consequent increase in bone fragility results in osteoporosis patients being prone to sustaining fractures. Although the majority of osteoporosis patients are postmenopausal women, it is not a female-only disease. It is estimated that one in three women and one in five men aged over 50 years will sustain an osteoporosis-related fracture.

Market Snapshot

  • Prolia will drive growth of the US market, while Forteo losses will halt growth in Japan and the EU.
  • The oral bisphosphonate alendronate dominates the treatment of all severities of low bone mass.
  • Forecasted growth in the total prevalence of osteopenia and osteoporosis will be driven by aging populations.
  • Biosimilar erosion and new anabolic entrants with superior efficacy are set to erode Forteo's blockbuster sales.
  • The arrival of Amgen's Evenity will be delayed due to safety issues.

Key Topics Covered:

Forecast: Osteoporosis

Overview

Executive Summary

Market Overview And Trends

Market Definition And Methodology

Actonel (Risedronate)

Boniva (Ibandronate)

Duavee ([Conjugated Estrogens + Bazedoxifene])

Edirol (Eldecalcitol)

Evenity (Romosozumab)

Evista (Raloxifene)

Forteo (Teriparatide) And Movymia (Teriparatide)

Fosamax (Alendronate)

Prolia (Denosumab)

Reclast (Zoledronic Acid)

Tymlos (Abaloparatide)

Primary Research Methodology

Treatment: Osteoporosis

Overview

Executive Summary

Primary Research Methodology

Disease Definition And Diagnosis

Patient Segmentation

Current Treatment Options

Prescribing Trends

Treatment Trends In Osteopenia

Treatment Trends In Osteoporosis

Treatment Trends In Severe Osteoporosis

Compliance Rates

Unmet Needs In Osteoporosis

Epidemiology: Osteoporosis

Overview

Executive Summary

Disease Background

Sources And Methodology

Forecast: Osteopenia

Forecast: Osteoporosis

Epidemiologist Insight

Strengths And Limitations

Appendix: Additional Sources

Marketed Drugs: Osteoporosis

Overview

Product Overview

Bisphosphonates

Estrogens And Serms

Calcitonin

Anabolic Therapies

Other Drug Classes

Product Profile: Forteo

Product Profile: Prolia

Product Profile: Tymlos

Pipeline: Osteoporosis

Overview

Clinical Pipeline Overview

Comparator Therapy

Recently Discontinued Drugs

Product Profile (Late Stage): Evenity

For more information about this report visit https://www.researchandmarkets.com/research/66lnk2/osteoporosis?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs